Artelo Biosciences' ART27.13 Reduces Chemotherapy-Induced Neuropathic Pain in Preclinical Study
Bitget2026/10/29 13:06- Artelo Biosciences will present nonclinical ART27.13 neuropathic pain findings today at the IASP 2026 World Congress on Pain in Bangkok.
- Repeated dosing reduced touch and heat sensitivity in male and female animals with paclitaxel-induced peripheral neuropathy.
- The ongoing Phase 2 CAReS trial includes pain endpoints to assess whether these effects translate to cancer patients.
- ART27.13, a once-daily oral treatment under development for cancer-related appetite and weight loss, could also address neuropathic pain.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Amid opposition to data centers, Musk doubles down: SpaceX (SPCX.US) plans to build a $24 billion computing center and gas power plant in Texas.
According to a public hearing notice published on the Starbase website, SpaceX plans to build, own, and operate a gas-fired power plant and a supercomputing facility at its company town in Starbase, Texas.
Crypto prices
More
